- Report
- November 2023
- 224 Pages
Global
€4361EUR$4,995USD£3,776GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$4,294USD£3,136GBP
- Report
- September 2024
- 239 Pages
China
From €3493EUR$4,000USD£3,024GBP
- Report
- September 2024
- 69 Pages
China
From €1572EUR$1,800USD£1,361GBP
- Report
- August 2024
- 123 Pages
China
From €1572EUR$1,800USD£1,361GBP
- Report
- January 2024
- 129 Pages
United States
€3318EUR$3,800USD£2,872GBP
- Report
- June 2021
- 50 Pages
China
From €2270EUR$2,600USD£1,965GBP
- Report
- July 2025
- 90 Pages
Global
From €3500EUR$4,294USD£3,136GBP
- Report
- August 2024
- 97 Pages
Global
From €3500EUR$4,294USD£3,136GBP
- Report
- February 2026
- 50 Pages
Global
From €2314EUR$2,650USD£2,003GBP
- Report
- August 2024
- 244 Pages
China
From €3493EUR$4,000USD£3,024GBP
- Report
- November 2021
- 747 Pages
Global
From €3493EUR$4,000USD£3,024GBP

Docetaxel is a chemotherapy drug used in the treatment of various types of cancer, including breast, ovarian, and non-small cell lung cancer. It is a semi-synthetic derivative of a natural substance found in the bark of the European yew tree. Docetaxel works by interfering with the growth of cancer cells, preventing them from dividing and spreading. It is usually administered intravenously, and is often used in combination with other drugs.
Docetaxel is a widely used oncology drug, and is often prescribed as a first-line treatment for certain types of cancer. It is also used in the treatment of advanced or metastatic cancer, and is sometimes used in combination with other drugs to improve the effectiveness of treatment.
Some companies in the Docetaxel market include Bristol-Myers Squibb, Pfizer, and Sanofi. Show Less Read more